| Data Sharing Statement |  |  |
|------------------------|--|--|
| Article<br>Info        | https://dx.doi.org/10.21037/tlcr-22-72   |  |
| Item                   | Question   | Authors' Response (place "-" if not applicable)  |
| 1                      | Would you like to share data collected for your study to others?   | Yes.   |
| 2                      | If not, would you like to share the reason for your decision?  | -  |
| 3                      | What data in particular will be shared?  | All data upon reasonable request.  |
| 4                      | Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code. | Statistical analysis plan will also be shared if requested.  |
| 5                      | When will data availability begin?   | From the publication date.   |
| 6                      | When will data availability end?   | Two years within the publication date.   |
| 7                      | To whom will you share the data?   | Medical oncologists who are interested in studies of immune checkpoint inhibitor-related pneumonitis.            |
| 8                      | For what type of analysis or purpose?  | For analysis to evaluate the safety of immune checkpoint inhibitors in lung cancer patients.                     |
| 9                      | How or where can the data/documents be obtained?   | Emails could be sent to the address below to obtain the shared data: hu.jie@zs-hospital.sh.cn.                   |
| 10                     | Any other restrictions?  | We may balance the potential benefits and risks for each request and then provide the data that could be shared. |